Zacks Investment Research on MSN
Agio's Pyrukynd gets approval for thalassemia in Europe
Agios Pharmaceuticals AGIO announced that its lead drug, Pyrukynd (mitapivat), an oral pyruvate kinase (PK) activator, has ...
Avanzanite entered an exclusive partnership with Agios in June 2025 to manage PYRUKYND commercialization across Europe European Commission will now review the CHMP’s opinion, with the final decision ...
PYRUKYND is the only medicine approved in the EU for adults with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia; Mitapivat is now approved for thal ...
The EC’s decision follows the positive opinion issued by the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) and is based on results from the global, randomised, ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Pyrukynd (mitapivat) is a prescription drug that’s used to treat hemolytic anemia. Pyrukynd comes as an oral tablet. Pyrukynd is used to treat hemolytic anemia in adults who have pyruvate kinase (PK) ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Despite missing the primary endpoint in a pediatric study, Agios says it remains steadfast in working to grow the reach of its pyruvate kinase (PK) activation franchise. Agios hopes to fill the ...
The FDA has approved Pyrukynd (mitapivat) for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency. The Food and Drug Administration (FDA) has approved Pyrukynd ® (mitapivat) ...
CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined ...
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results